Therapeutic outcomes of papillary thyroid carcinomas with tumors more advanced than T1N0M0

Radiotherapy and Oncology

Volumn 89, Issue 1, 2008, Pages 97-104

  Lin, Jen Der ^a   Lin, Kun Ju ^a   Chao, Tzu Chieh ^a   Hseuh, Chuen ^a   Tsang, Ngan Ming ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

131I therapy; Cancer related mortality; Thyroglobulin; Total thyroidectomy

Indexed keywords

IODINE 131; THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

ADULT; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PAPILLARY CARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME;

EID: 54849192000     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.05.011     Document Type: Article

References (25)

1. Alzahrani A.S., Mohamed G., Al Shammary A., et al. Long-term course and predictive factors of elevated serum thyroglobulin and negative diagnostic radioiodine whole body scan in differentiated thyroid cancer. J Endocrinol Invest 28 (2005) 540-546
2. Bhattacharyya N., and Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann Otol Rhinol 115 (2006) 607-610
3. Cerutti J.M., Oler G., Michaluart Jr. P., et al. Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis. Cancer Res 67 (2007) 7885-7892
4. Chow S.M., Law S.C., Au S.K., et al. Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute. Head Neck 24 (2002) 670-677
5. Cooper D.S., Doherty G.M., Haugen B.R., et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16 (2006) 109-142
6. Delellis R.A., Lloyd R.V., Heitx P.U., et al. Pathology and genetics of tumors of endocrine organs. World Health Organization of tumours (2004), IARC, Lyon
7. Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 9 (2006) 2892-2899
8. Görges R., Maniecki M., Jentzen W., et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 153 (2005) 49-55
9. Grünwald F., Menzel C., Fimmers R., et al. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer. J Nucl Med 37 (1996) 1962-1964
10. Handkiewicz-Junak D., Wloch J., Roskosz J., et al. Total thyroidectomy and adjuvant radioiodine treatment independently decrease locoregional recurrence risk in childhood and adolescent differentiated thyroid cancer. J Nucl Med 48 (2007) 879-888
11. Lin J.D. Papillary thyroid carcinoma with lymph node metastases. Growth Factors 25 (2007) 41-49
12. Lin J.D., Chen S.T., Chao T.C., et al. A 29-year retrospective review of 2473 thyroid cancer in one institution. Thyroid 17 (2007) 535-541
13. Menzel C., Grünwald F., Schomburg A., et al. High-dose radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med 37 (1996) 1496-1503
14. Milas M., Mazzaglia P., Chia S.Y., et al. The utility of peripheral thyrotropin mRNA in the diagnosis of follicular neoplasms and surveillance of thyroid cancers. Surgery 141 (2007) 137-146
15. Mishra A., Pal L., and Mishra S.K. Distribution of Na(+)/I (-) symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study. World J Surg 31 (2007) 1737-1742
16. Pacini F., Schlumberger M., Dralle H., Elisei R., et al. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154 (2006) 787-803
17. Podnos Y.D., Smith D.D., Wagman L.D., et al. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol 96 (2007) 3-7
18. Riesco-Eizaguirre G., and Santisteban P. A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol 155 (2006) 495-512
19. Sisson J.C., Giordano T.J., Jamadar D.A., et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer 78 (1996) 2184-2192
20. Sobin L.H. UICC. In: Wittekind Ch. (Ed). TNM classification of malignant tumors. 6th ed. (2002), Wiley-Liss, New York 52-56
21. Song H., He B., Prideaux A., et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med 47 (2006) 1985-1994
22. Vassilopoulou-Sellin R., Schultz P.N., and Haynie T.P. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy. Cancer 78 (1996) 493-501
23. Verkooijen R.B., Smit J.W., Romijn J.A., et al. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer. Eur J Endocrinol 155 (2006) 801-806
24. Vermeer-Mens C.J., Goemaere N.T., Kuenen-Boumeester V., et al. Childhood papillary thyroid carcinoma with miliary pulmonary metastases. J Clin Oncol 36 (2006) 5788-5789
25. Zhang D.D., Zhou X.H., Freeman D.H., et al. A non-parametric method for the comparison of partial areas under ROC curves and its application to large health care data sets. Stat Med 21 (2002) 701-715